CN106344926A - Post-crosslinked gel plaster substrate and method for preparing medicated plaster - Google Patents
Post-crosslinked gel plaster substrate and method for preparing medicated plaster Download PDFInfo
- Publication number
- CN106344926A CN106344926A CN201610930431.7A CN201610930431A CN106344926A CN 106344926 A CN106344926 A CN 106344926A CN 201610930431 A CN201610930431 A CN 201610930431A CN 106344926 A CN106344926 A CN 106344926A
- Authority
- CN
- China
- Prior art keywords
- acid
- substrate
- salt
- linked gel
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
Abstract
The invention discloses a post-crosslinked gel plaster substrate which is composed of an adhesive, a plasticizer, a framework, a transdermal accelerator, a crosslinking agent and a buffering agent. The buffering agent is at least one of hydroxy acid and salts thereof, short-chain fatty acids and salts thereof, and acidic amino acids and salts thereof. Since the substrate prescription comprises the buffering agent, the drugs basically can not influence the post-crosslinking reaction speed of the substrate after being added, and thus, the crosslinking reaction speed of the substrate is stabler. The pH value of the substrate is approximate to the inherent pH value of the drugs, thereby ensuring the drugs to be in the appropriate polar state, and being beneficial to the transdermal absorption of the drugs. The crosslinking speed of the substrate is not sensitive to the acid or alkali, thereby lowering the requirements for the acid/alkali addition accuracy in the production process, reducing the product quality difference among batches, and enhancing the industrial applicability of the substrate.
Description
Technical field
The present invention relates to a kind of rear cross-linked gel plaster base, present invention simultaneously relates to this rear cross-linked gel plaster base preparation contains
The method of medicine paste unguentum, belongs to technical field of polymer materials and pharmaceutical technology field.
Background technology
The external plaster recording in pharmacopeia and ministry standard at present mainly has rubber-emplastrum, black plaster, fat-soluble pressure-sensitive
Sticker cream, cataplasma etc..Not only drug loading is too little for rubber-emplastrum, and has quite a few patient that rubber allergy occurs.Black
Plaster has the characteristics that drug loading is big, persistent, but its substrate is Oleum Sesami after exploding withered medical material refines with Plumbum preparatium at high temperature
Form, " fire-toxin " not only not eliminated completely has hypersensitive, and it is very high that in preparation, people is carried with harmful lead element content.
In addition because medical material need to be tempered with Oleum Sesami in preparation process, under high temperature, loss of effective components is also very big.Need when black plaster uses
Heating deliquescing ability Pasting, using also inconvenient.The presently used pressure sensitive adhesive of fat-soluble pressure sensitive adhesive plaster mainly have polyisobutylene,
Silicone pressure-sensitive adhesive and pressure-sensitive acrylate.The breathability of Polyisobutylene PSA is very poor and no water absorption, uses polyisobutylene
The patch that pressure sensitive adhesive is obtained hinders skin sweat secretion, and patch adhesiveness can be made after skin perspiration to decline and cause patch to take off
Fall.Silicone pressure-sensitive adhesive breathability, flexibility are all preferable, but drug loading too little (after more than 5%, adhesiveness meeting straight line declines), price
Expensive.Polyacrylic resin class pressure sensitive adhesive equally exists poor air permeability and no absorptive defect.The above of such pressure sensitive adhesive lacks
Be trapped in painting cream thickness and drug loading larger in the case of seem especially prominent.Catablasm base material is hydrophilic matrix, has and can inhale
Receive perspiration, using comfortable, drug transdermal is good, the features such as can repeatedly notice, but there is initial bonding strength, holding power is not enough, after absorbing sweat
The problems such as decline easy " rotten cream " due to cohesiveness, in addition its preparation technology is more complicated, and parameter is difficult to control to, and is unfavorable for industry
Metaplasia is produced.Disadvantages described above leads to cataplasma product in the market little.
In patent zl201010104420.6, (achievement in research of inventor's early stage) discloses a kind of rear cross-linked hydrophilic patch
Cream base matter.Due to this invention matrix formulations moisture-free, the cross-linking reaction of plaster stroma is placed in plaster patch after workshop
Carry out after skin perspiration, therefore being produced with this substrate can be using the technique directly heating melt coating, technique during plaster
Simplicity, condition is easy to control, overcomes crosslinking rate shortcoming very rambunctious when Babu cream produces.Remain black plaster, bar simultaneously
The big advantage of plaster ointment drug loading, makes drug loading maximum can reach 30%, far above existing various kinds of substrates.This substrate has no simultaneously
Allergy, can repeatedly take off patch, sweat-absorbing breathable, can 0 DEG C stored below, safety is good many advantages, such as.
But, find in the follow-up study of inventor, if the ph value of the ph value of this substrate and medicine after absorbing sweat
Between there is gap, the ph environment of medicine presence can be changed after substrate and medicament mixed and affect the Transdermal absorption of medicine, simultaneously
Medicine also can affect substrate crosslinking rate it is therefore desirable to set up in substrate one with added enter the close buffering of medicine ph value
System.When preparing medicated adhesive plaster with the gel-type vehicle containing buffer system, medicine is added medicine after substrate crosslinked to substrate fast
The impact of degree is smaller, is conducive to producing stay-in-grade product.And because the ph value of buffer system is fitted close to medicine
The ph environment of preferably absorption also relatively coincide, and is conducive to improving the percutaneous absorbtion rate of medicine.
Content of the invention
The purpose of the present invention is the problem existing for prior art, provides a kind of transdermal absorption factor height, crosslinking rate not
Affected by medicine ph value, rear cross-linked gel plaster stroma that release is steadily lasting.
The rear cross-linked gel plaster stroma of the present invention, is to carry out component by the raw material of following percentage by weight:
Adhesive agent 10-48%, plasticizer 10-50%, skeleton agent 1-20%, transdermal enhancer 0.5-15%, cross-linking agent 0.5-8%, delay
Electuary 4-40%.
Buffer agent is hydroxy acid and its salt (includes tartaric acid, citric acid, lactic acid, malic acid and its sodium, potassium, calcium salt, ethanol
At least one in sour sodium), short-chain fatty acid and its salt (include at least in acetic acid, propanoic acid, butanoic acid and its sodium, potassium, calcium salt
Kind), at least one in acidic amino acid and its salt (including glutamic acid, aspartic acid and its sodium, potassium, calcium salt).
In the case that medicine is larger on the tack impact of plaster substrate, matrix components in matrix components, can also be added
Gross weight 5-20% pressure-sensitive acrylate or Polyvinylalkylethers class, make the viscous adhesiveness of plaster substrate and water absorption more
Good.
Above-mentioned adhesive agent is Polyvinylpyrrolidone, polyvinyl alcohol or hydroxypropyl cellulose；Plasticizer is molecular weight 200
Polyethylene Glycol between ~ 1000 or ethanol；Skeleton agent is Carbomer, polyacrylic acid and its sodium salt；Transdermal enhancer be propylene glycol,
Azone, Oleic acid or traditional medicine volatile oil；Cross-linking agent is aluminum glycinate, aluminum sulfate, aluminum chloride, Alumen or compound aluminium salt.
The method that above-mentioned rear cross-linked gel plaster stroma prepares drug containing emplastrum, is by each for substrate component and not aqueous medicine
After thing component mix homogeneously, it is heated to 50 ~ 110 DEG C, stirs into cream, obtain pastille creme；Again by pastille creme at 50 ~ 110 DEG C
At a temperature of coat non-woven fabrics, then cover adherent layer and obtain final product emplastrum product.
The liquid component of above-mentioned matrix components and drug component also can be mixed respectively with solid constituent: will substrate solid
Component water-free drug powder mix homogeneously obtains mixed-powder；The liquid component of substrate is mixed homogeneously with liquid medicament component
Obtain mixing liquid；Again by after mixed-powder and mixing liquid mix homogeneously, it is heated to 50 ~ 110 DEG C, stirs into cream, contained
Ointment material；Again pastille creme is coated non-woven fabrics at a temperature of 50 ~ 110 DEG C, then cover adherent layer and obtain final product emplastrum product.
Above-mentioned not aqueous drug component is chemicalses, Chinese medicine extract powder, Chinese crude drug fine powder or traditional medicine volatile oil.
The present invention, compared with plaster stroma of the prior art, has the advantage that
1st, due in substrate prescription, there is ph buffer system, after medicine adds, medicine is not substantially to substrate post-crosslinking reaction speed
Degree impacts, and substrate cross-linking reaction speed is more stable；
2nd, due to there is ph buffer system in substrate prescription so that substrate ph and the intrinsic ph value of medicine are close, therefore substrate
Environment can ensure that medicine is in suitable polarization state, is conducive to the Transdermal absorption of medicine substantially；
3. due in substrate prescription, there is ph buffer system, make the impact to substrate crosslinking rate for the acid-base material become insensitive,
The differences between batches of product quality can be reduced by reducing the requirement of the accuracy that in production process, acid-base material fed intake further,
Improve the industrial usability of substrate.
Specific embodiment
Below by specific embodiment, the method for the component of substrate of the present invention and preparation drug containing emplastrum is made into one
Step explanation.
Embodiment one, the preparation of infant spleen-tonifying plaster
Matrix components: 540 grams of Polyethylene Glycol, 10 grams of lactic acid, 30 grams of sodium lactate, 6 grams of azone, 50 grams of Carbomer, polyvinyl pyrrole
484 grams of alkanone, 120 grams of aluminum sulfate；
Drug component: 52 grams of Flos Caryophylli, 52 grams of Fructus Evodiae, 52 grams of Galla Chinensiss, 90 grams of Magnetitum, 5.5 grams of g of Borneolum Syntheticum, artificial Moschuss 0.2
Gram；
Preparation technology:
1st, Flos Caryophylli, Fructus Evodiae, Galla Chinensiss, Magnetitum are ground into fine powder, cross 100 mesh sieves；Borneolum Syntheticum, artificial Moschuss are finely ground, and above-mentioned
Fine powder facing-up, mixes, obtains medicated powder；
2nd, Polyethylene Glycol, lactic acid, sodium lactate, azone mix homogeneously are obtained mixing liquid；
3rd, Carbomer, Polyvinylpyrrolidone, aluminum sulfate and step 1 gained medicated powder are sequentially added the mixed liquor of step 2 gained
Mix homogeneously in body, is heated to 100 DEG C, stirs into cream, obtains pastille creme；
4th, pastille creme be heated to 95 DEG C insulation, non-woven fabrics are coated using rolling process, then cover adherent layer obtain final product plaster produce
Product.
Embodiment two, the preparation of warm umbilica sticking plaster
Matrix components: 18 grams of Carbomer, 90 grams of Polyvinylpyrrolidone, 10 grams of sodium propionate, 21.5 grams of crystal aluminum chloride, poly- second two
165 grams of alcohol, 5 grams of propanoic acid, 2.5 grams of azone, 10 grams of ethanol, 3 grams of propylene glycol；
Drug component: each 80 grams of Radix Angelicae Sinensis, the Radix Angelicae Dahuricae, the Radix Linderae, Fructus Foeniculi, Fructus Anisi Stellati, Rhizoma Cyperi, 40 grams of the Radix Aucklandiae, 20 grams of Fructus Caryophylli, meat
20 grams of osmanthus, 20 grams of Lignum Aquilariae Resinatum, 20 grams of Olibanum, 20 grams of Myrrha, 3 grams of Moschus；
Preparation technology:
1st, Radix Angelicae Sinensis, the Radix Angelicae Dahuricae, the Radix Linderae, Fructus Foeniculi, Fructus Anisi Stellati, Rhizoma Cyperi, the Radix Aucklandiae, Fructus Caryophylli, Cortex Cinnamomi, Lignum Aquilariae Resinatum are with 75～85% ethanol
Reflux, extract, reclaims ethanol and concentrates, and extract powder is pulverized to obtain in 60 DEG C of vacuum drying；Olibanum, Myrrha, Moschus finely ground with above-mentioned extractum
Powder facing-up, mixes, obtains medicated powder；
2nd, will be after Carbomer, Polyvinylpyrrolidone, sodium propionate, crystal aluminum chloride mix homogeneously more mixed with step 1 gained medicated powder
Close uniformly, obtain mixed-powder；
3rd, Polyethylene Glycol, propanoic acid, azone, ethanol, mixed with propylene glycol are uniformly obtained mixing liquid；
4th, by after step 2,3 mixed-powders obtaining and mixing liquid again mix homogeneously, it is heated to 110 DEG C, stirs into cream, obtain
To pastille creme；
5th, pastille creme be heated to 90 DEG C insulation, non-woven fabrics are coated using extrusion molding, then cover adherent layer obtain final product plaster produce
Product.
Embodiment three, general pain are by the preparation of silt plaster
Matrix components: 15 grams of Carbomer, 290 grams of Polyvinylpyrrolidone, 10 grams of glutamic acid, 40 grams of sodium glutamate, aluminum sulfate 72
Gram, 324 grams of Polyethylene Glycol, 2 grams of azone, 3 grams of Oleic acid；
Drug component: 30 grams of Radix Gentianae Macrophyllae, 90 grams of Semen Persicae, 60 grams of Radix Glycyrrhizae, 60 grams of Oletum Trogopterori, 90 grams of Radix Achyranthis Bidentatae, 60 grams of Pheretima, Rhizoma Chuanxiong 60
Gram, 90 grams of Flos Carthami, 30 grams of Rhizoma Et Radix Notopterygii, 60 grams of Radix Angelicae Sinensis, 30 grams of Rhizoma Cyperi, 60 grams of Myrrha；
Preparation technology:
1st, by Radix Gentianae Macrophyllae, Semen Persicae, Radix Glycyrrhizae, Oletum Trogopterori, Radix Achyranthis Bidentatae, Pheretima extracting in water twice, extracting solution adds ethanol to 60% precipitation
Reclaim ethanol and obtain concentrated solution；
2nd, Rhizoma Chuanxiong, Flos Carthami, Rhizoma Et Radix Notopterygii, Radix Angelicae Sinensis, Rhizoma Cyperi are added water 8 times and extract, aqueous extract is merged with step 1 gained concentrated solution, enters
One step concentrates, and dry, pulverize, obtains extract powder；Volatile oil saves backup；Myrrha is ground into fine powder；
3rd, Carbomer, Polyvinylpyrrolidone, glutamic acid, sodium glutamate, aluminum sulfate mix homogeneously are obtained mixed-powder；Again with
Step 2 medicated powder mix homogeneously, obtains pastille powder.
4th, Polyethylene Glycol, azone, Oleic acid and step 2 gained volatile oil mix homogeneously are obtained mixing liquid；
5th, the powder obtaining step 3 and step 4 and liquid after mix homogeneously, are heated to 70 DEG C, stir into cream, contained again
Ointment material；
6th, by pastille creme be heated to 85 DEG C insulation, non-woven fabrics are coated using rolling process, then cover adherent layer be plaster produce
Product.
Example IV, the preparation of sun plaster
Matrix components: 160 grams of Polyethylene Glycol, 2 grams of propylene glycol, 5 grams of potassium lactate, 40 grams of polyvinyl ethyl ether, 8 grams of Carbomer, poly-
150 grams of vinylpyrrolidone, 40 grams of Alumen, 54 grams of sodium polyacrylate；
Drug component: 90 grams of Oleum menthae；
Preparation technology:
1st, Oleum menthae, Polyethylene Glycol, propylene glycol, potassium lactate, polyvinyl ethyl ether mix homogeneously are obtained mixing liquid；
2nd, Carbomer, Polyvinylpyrrolidone, Alumen, sodium polyacrylate mix homogeneously are obtained mixed-powder；
3rd, by after above-mentioned mixed-powder and mixing liquid again mix homogeneously, it is heated to 90 DEG C, stirs into cream, obtain containing ointment
Material；
4th, pastille creme is incubated at 85 DEG C, non-woven fabrics are coated using extrusion molding, then cover adherent layer and obtain final product plaster product
Product.
Embodiment five, the preparation of Piroxicam plaster
Matrix components: 35 grams of Carbomer, 80 grams of Polyvinylpyrrolidone, 8 grams of aluminum sulfate, 5 grams of sodium glutamate, Polyethylene Glycol 120
Gram, 2 grams of azone, 10 grams of propylene glycol, 10 grams of ethanol；
Drug component: 15 grams of Piroxicam；
Preparation technology:
1st, Piroxicam, Carbomer, Polyvinylpyrrolidone, aluminum sulfate, sodium glutamate mix homogeneously are obtained mixed-powder；
2nd, Polyethylene Glycol, azone, propylene glycol, ethanol mix homogeneously are obtained mixing liquid；
3rd, the mixed-powder obtaining step 1 and step 2 and mixing liquid after mix homogeneously, are heated to 70 DEG C, stir into again
Cream, obtains pastille creme；
4th, pastille creme is incubated at 85 DEG C, non-woven fabrics are coated using rolling process, then cover adherent layer and obtain final product plaster product
Product.
In order to the skin penetration rate of the medicinal plaster of plaster stroma preparation of the present invention is described, we are warm with embodiment two preparation
The general pain of umbilica sticking plaster and embodiment three preparation by carrying out body skin permeation rate test as a example silt plaster, and with equal conditions,
Zl201010104420.6 prepares medicinal plaster (embodiment 3,4) and compares.
Experiment 1: warm umbilica sticking plaster prepared by patent zl201010104420.6 embodiment 3 is prepared with the embodiment of the present invention 2
Warm umbilica sticking plaster be affixed on through depilation process recover after rabbit skin, using residue mensuration, with ferulic acid for index components contrast
Two kinds of preparation medicines in body skin permeation rate, data see table:
Test 2: general pain prepared by patent zl201010104420.6 embodiment 4 is prepared with the embodiment of the present invention 4 by silt plaster
General pain by silt plaster be affixed on through depilation process recover after rabbit skin, using residue mensuration, with gentiopicrin for index become
Point contrast two kinds of preparation medicines in body skin permeation rate, data see table:
Above-mentioned experiment shows, under equal conditions, the percutaneous rate of the medicine paste unguentum of substrate of the present invention preparation is apparently higher than special
The medicine paste unguentum of the substrate preparation of sharp zl201010104420.6.
Claims (10)
1. a kind of rear cross-linked gel plaster stroma, is to carry out component by the raw material of following percentage by weight:
Adhesive agent 10-48%, plasticizer 10-50%, skeleton agent 1-20%, transdermal enhancer 0.5-15%, cross-linking agent 0.5-8%, delay
Electuary 4-40%.
2. as claimed in claim 1 a kind of rear cross-linked gel plaster stroma it is characterised in that: described buffer agent be hydroxy acid and its
At least one in salt, short-chain fatty acid and its salt, acidic amino acid and its salt.
3. as claimed in claim 2 a kind of rear cross-linked gel plaster stroma it is characterised in that: described hydroxy acid and its salt are winestone
Acid, citric acid, lactic acid, malic acid and its sodium, potassium, at least one in calcium salt, or sodium glycollate.
4. as claimed in claim 2 a kind of rear cross-linked gel plaster stroma it is characterised in that: described short-chain fatty acid and its salt are
Acetic acid, propanoic acid, butanoic acid and its sodium, potassium, at least one in calcium salt.
5. as claimed in claim 2 a kind of rear cross-linked gel plaster stroma it is characterised in that: described acidic amino acid and its salt are
Glutamic acid, aspartic acid and its sodium, potassium, at least one in calcium salt.
6. as claimed in claim 1 a kind of rear cross-linked gel plaster stroma it is characterised in that: raw material components also include matrix components
The pressure-sensitive acrylate of gross weight 5-20% or Polyvinylalkylethers class.
7. as described in claim 1 ~ 6 any one after cross-linked gel plaster stroma it is characterised in that: described adhesive agent be poly- second
Alkene pyrrolidone, polyvinyl alcohol or hydroxypropyl cellulose；Described plasticizer is Polyethylene Glycol between 200 ~ 1000 for the molecular weight
Or ethanol；Described skeleton agent is Carbomer, polyacrylic acid and its sodium salt；Described transdermal enhancer be propylene glycol, azone, Oleic acid or
Traditional medicine volatile oil；Described cross-linking agent is aluminum glycinate, aluminum sulfate, aluminum chloride, Alumen or compound aluminium salt.
8. a kind of method that rear cross-linked gel plaster stroma prepares drug containing emplastrum as claimed in claim 1, is that substrate is each
After component is mixed homogeneously with not aqueous drug component, it is heated to 50 ~ 110 DEG C, stirs into cream, obtain pastille creme；Again by pastille
Creme coats non-woven fabrics at a temperature of 50 ~ 110 DEG C, then covers adherent layer and obtain final product emplastrum product.
9. as claimed in claim 1 a kind of rear cross-linked gel plaster stroma prepare drug containing emplastrum method it is characterised in that:
Described not aqueous drug component is chemicalses, Chinese medicine extract powder, Chinese crude drug fine powder or traditional medicine volatile oil.
10. a kind of method that rear cross-linked gel plaster stroma prepares drug containing emplastrum as claimed in claim 1, its feature exists
In: the solid constituent water-free drug powder mix homogeneously of substrate obtains mixed-powder；The liquid component of substrate and liquid medicine
Thing component mix homogeneously obtains mixing liquid；Again by after mixed-powder and mixing liquid mix homogeneously, it is heated to 50 ~ 110 DEG C, stirs
Mix cream, obtain pastille creme；Again pastille creme is coated non-woven fabrics at a temperature of 50 ~ 110 DEG C, then cover adherent layer and be
Obtain emplastrum product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610930431.7A CN106344926A (en) | 2016-10-31 | 2016-10-31 | Post-crosslinked gel plaster substrate and method for preparing medicated plaster |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610930431.7A CN106344926A (en) | 2016-10-31 | 2016-10-31 | Post-crosslinked gel plaster substrate and method for preparing medicated plaster |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106344926A true CN106344926A (en) | 2017-01-25 |
Family
ID=57865252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610930431.7A Pending CN106344926A (en) | 2016-10-31 | 2016-10-31 | Post-crosslinked gel plaster substrate and method for preparing medicated plaster |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106344926A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108653523A (en) * | 2018-08-17 | 2018-10-16 | 吴长凤 | One analgesic bone cold compress gel and preparation method thereof |
| CN112353862A (en) * | 2020-12-01 | 2021-02-12 | 陕西摩美得气血和制药有限公司 | Traditional Chinese medicine gel plaster for treating children cough with lung heat and preparation method thereof |
| CN115738371A (en) * | 2022-12-05 | 2023-03-07 | 山东柳新堂健康产业有限公司 | Subcritical double-solvent extraction method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1372463A (en) * | 1999-07-27 | 2002-10-02 | 久光制药株式会社 | Patches for external use |
| CN101785864A (en) * | 2010-01-30 | 2010-07-28 | 魏舒畅 | Post-crosslinking hydrophilic patch substrate and preparation method thereof |
-
2016
- 2016-10-31 CN CN201610930431.7A patent/CN106344926A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1372463A (en) * | 1999-07-27 | 2002-10-02 | 久光制药株式会社 | Patches for external use |
| CN101785864A (en) * | 2010-01-30 | 2010-07-28 | 魏舒畅 | Post-crosslinking hydrophilic patch substrate and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 中国人民解放军总后勤部卫生部: "《生物药剂学》", 31 March 1985 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108653523A (en) * | 2018-08-17 | 2018-10-16 | 吴长凤 | One analgesic bone cold compress gel and preparation method thereof |
| CN112353862A (en) * | 2020-12-01 | 2021-02-12 | 陕西摩美得气血和制药有限公司 | Traditional Chinese medicine gel plaster for treating children cough with lung heat and preparation method thereof |
| CN115738371A (en) * | 2022-12-05 | 2023-03-07 | 山东柳新堂健康产业有限公司 | Subcritical double-solvent extraction method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101774342B1 (en) | Hydrogel maskpack composition, Hydrogel maskpack and the preparing method thereof | |
| KR101015491B1 (en) | Patch | |
| US20040156886A1 (en) | Sheet-like patch agent | |
| KR20050017556A (en) | Temperature Sensitive State-Changing Hydrogel Composition and Method for their Preparation | |
| CN110755410B (en) | Chinese medicine gel plaster and its matrix | |
| US20110300198A1 (en) | Hydrocolloid - essential oil patches | |
| CN106344926A (en) | Post-crosslinked gel plaster substrate and method for preparing medicated plaster | |
| TWI542368B (en) | Patch containing serotonin receptor antagonist | |
| CN109069393B (en) | Cosmetic alcohol gel film and method for producing same | |
| KR20020011964A (en) | Sheet-form adhesive preparation | |
| JP5350575B2 (en) | Sheet-like pack and method for producing the same | |
| CN112022919A (en) | Percutaneous-absorption artemisia vulgaris oil carrier gel and preparation method thereof | |
| JPH10512245A (en) | Compositions and methods for transdermal delivery of acid labile drugs | |
| US20080081056A1 (en) | Depolymerized polysaccharide-based hydrogel adhesive and methods of use thereof | |
| WO2005105060A1 (en) | Plaster | |
| CN101288772B (en) | Novel medical hot melt resin carrier gel matrix and its preparation method and application | |
| CN101612141B (en) | Buprenorphine patch | |
| CN101785864B (en) | Post-crosslinking hydrophilic patch substrate and preparation method thereof | |
| CN1883450A (en) | A hydrophilic gel plaster substrate | |
| CN101084883A (en) | Capsaicin percutaneous controlled-release paster and preparation method | |
| CN109481422B (en) | Graphene oxide electrothermal film transdermal patch | |
| CN102940777A (en) | Cough relieving and sore-throat relieving cataplasm and preparation method thereof | |
| CN1201663A (en) | Substrate for medical paste | |
| CN112957346A (en) | Gentiana macrophylla cataplasm and preparation method thereof | |
| CN112516115B (en) | Plaster containing flurbiprofen and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170125 |